Thermo Fisher Scientific Launches Center of Excellence in Immunotherapy Program

Washington University School of Medicine first partner to adopt company-centric workflow for immuno-oncology research

Thursday, December 8, 2016 8:00 am EST


"Integrating Thermo Fisher Scientific’s full complement of instrumentation and reagents provides great value to our workflow"

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced its Center of Excellence in Immunotherapy Program designed to build strategic collaborations and accelerate research and clinical trials in immuno-oncology around the globe. The Washington University School of Medicine is the first institution to partner with the company as part of the new program and will incorporate a complete workflow for biomarker work from novel whole transcriptome technologies to single cell assays.

Dr. Robert Schreiber, Alumni Professor, Pathology and Immunology; Professor, Molecular Microbiology, and Director of the Center for Human Immunology and Immunotherapy Programs (CHiiPs) at Washington University School of Medicine, is leading research at CHiiPs to develop individualized therapeutic cancer vaccines. Schreiber and colleagues are employing genomic and bioinformatic approaches to identify mutations within tumors that form tumor-specific neoantigens.

Additionally, the research team is working to produce vaccines designed to target neoantigens that are unique to a variety of cancer types and to each patient – essentially developing a personalized method to address the disease. The potential clinical course of each treated patient could then be followed by monitoring the evolution of their tumor-specific immune response and the effects of the vaccine on their tumor burden.

“Integrating Thermo Fisher Scientific’s full complement of instrumentation and reagents provides great value to our workflow,” said Schreiber. “The capacity to assess expression of mutant neoantigens and other tumor specific immune targets in clinical research samples via mass spectrometry, and assess the therapeutic effects of our vaccines using transcriptome arrays, in situ RNA assays, and immunoassays provide us with the sensitivities and specificities we need to attack this novel therapeutic program. We are confident this new relationship will allow us to make rapid advances towards our scientific and therapeutic goals.”

As part of the Center of Excellence Program, members of the CHiiPs Immunomonitoring Laboratory will utilize a Thermo Fisher technology-led workflow, including transcriptomic profiling of clinical trial samples, deep immune profiling with immuno-assays, antigen discovery using the latest generation of mass spectrometry technologies and RNA-ISH technologies to explore novel targets through in-situ analysis of tumor microenvironments.

“Dr. Schreiber is a pioneer in developing innovative approaches to turn the immune system against cancer, and we are delighted to include his team of researchers into our newly launched program,” said Alex Forrest-Hay, director of business development for Thermo Fisher Scientific. “We believe that establishing strategic partnerships with world-leading research laboratories is essential to accelerating biomarker development and to the future success of the next generation of immunotherapies.”

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit


Thermo Fisher Scientific
Mauricio Minotta, +1 760-929-2456

Thermo Fisher Tweets

View our 2 part Direct PCR webinar series now. hour 52 min ago
Watch Kim Kelderman, VP & GM, Genetic Analysis, introduce the new Applied Biosystems SeqStudio Genetic Analyzer… hours 31 min ago
In the meantime, can you plz email, which is the most up-to-date address? (2/2)-3 hours 55 min ago
We are really sorry that you got that message & are investigating the cause. We apologize sincerely . (1/2)-3 hours 57 min ago
Brilliant new western blot instruments are on the horizon! Be the first to know more. hours 47 min ago